Sign In
Buy XBI
$129.83
+2.07 (+1.62%)
At Close: Jun 03, 2026
Achieve: Late-Stage Biotech Developing Vaping And Smoking Cessation Drugs
04:37pm, Tuesday, 25'th Apr 2023
Achieve: Late-Stage Biotech Developing Vaping And Smoking Cessation Drugs.
Travere: Pegtibatinase Takes The Lead In The HCU Treatment Race
10:42pm, Monday, 24'th Apr 2023
Travere: Pegtibatinase Takes The Lead In The HCU Treatment Race.
XBI: Uncorrelated Growth Capitalizing On The M&A Tidal Wave In Pharma
11:13am, Friday, 21'st Apr 2023
We believe the M&A wave in the biotech sector presents a prime opportunity for investors to profit from the rising valuations of small and mid-cap firms in SPDR® S&P Biotech ETF. Big pharma companies
Biotech ETFs' Performance Deserves A Look
03:38pm, Wednesday, 19'th Apr 2023
Biotech comes with a great many positive externalities for society, and can be a big positive for portfolios right now.
Leveraged Biotech ETFs: Hold LABU, Sell LABD
02:13pm, Wednesday, 19'th Apr 2023
Leveraged Biotech ETFs: Hold LABU, Sell LABD
Final Trades: XBI, BXP, SPY & MRK
06:41pm, Monday, 17'th Apr 2023
The final trades of the day with CNBC's Melissa Lee and the Fast Money traders.
The FDA Is Resuming Drug Lab Inspections in China. These Biotechs Could Benefit.
02:45pm, Friday, 14'th Apr 2023
China's pandemic-era travel restrictions paused approvals on some new drugs. The end of Zero Covid means the pipeline will reopen.
Final Trades: Biotech, Defense, Thermo Fisher & more
02:21pm, Thursday, 13'th Apr 2023
The "Halftime Report" traders give their top picks to watch for the second half.
XBI: Derisking Biotech Exposure Through An ETF
09:43am, Tuesday, 04'th Apr 2023
Biotech names tend to have some of the best upsides for a well-informed investor. For a majority of us understanding the industry is no easy task and many individual biotech names can be fraught with
Is SPDR S&P Biotech ETF (XBI) a Strong ETF Right Now?
07:40am, Tuesday, 28'th Mar 2023
Smart Beta ETF report for XBI
Passive Funds' Ownership of US Stocks Soars
10:22pm, Monday, 27'th Mar 2023
Share prices appear unaffected as passive ETF and mutual fund stakes hit 19%, analysis says.
XBI: Underperformance Of Small Cap Biotech Likely To Continue
08:41am, Saturday, 25'th Mar 2023
XBI sits 58% below its all-time high. Yet I still don't think it is a good investment here. There are too many risk factors for the smaller biotech stocks this ETF owns, and tighter lending conditions
Should You Invest in the SPDR S&P Biotech ETF (XBI)?
07:41am, Thursday, 16'th Mar 2023
Sector ETF report for XBI
The 7 Best Biotech ETFs to Buy for Exposure to the Healthcare Sector
11:31am, Wednesday, 15'th Mar 2023
Amid the trying circumstances in the market right now, investors may be well served to target the best biotech ETFs to buy. Fundamentally, these exchange-traded funds benefit from permanent relevance.
SVB fallout: The impacts on the biotech sector
09:59am, Monday, 13'th Mar 2023
CNBC's Meg Tirrell reports on how the SVB fallout could impact biotech investors.
